| Literature DB >> 32411249 |
Rui D Alvites1,2, Mariana V Branquinho1,2, Ana R Caseiro1,2,3,4, Irina Amorim5,6,7, Sílvia Santos Pedrosa1,2, Alexandra Rêma5, Fátima Faria5, Beatriz Porto8, Cláudia Oliveira8, Paula Teixeira9, Rui Magalhães9, Stefano Geuna10, Artur S P Varejão11,12, Ana C Maurício1,2.
Abstract
Stem/stromal cell-based therapies are a branch of regenerative medicine and stand as an attractive option to promote the repair of damaged or dysfunctional tissues and organs. Olfactory mucosa mesenchymal stem/stromal cells have been regarded as a promising tool in regenerative therapies because of their several favorable properties such as multipotency, high proliferation rate, helpful location, and few associated ethical issues. These cells are easily accessible in the nasal cavity of most mammals, including the rat, can be easily applied in autologous treatments, and do not cope with most of the obstacles associated with the use of other stem cells. Despite this, its application in preclinical trials and in both human and animal patients is still limited because of the small number of studies performed so far and to the nonexistence of a standard and unambiguous protocol for collection, isolation, and therapeutic application. In the present work a validation of a protocol for isolation, culture, expansion, freezing, and thawing of olfactory mucosa mesenchymal stem/stromal cells was performed, applied to the rat model, as well as a biological characterization of these cells. To investigate the therapeutic potential of OM-MSCs and their eventual safe application in preclinical trials, the main characteristics of OMSC stemness were addressed.Entities:
Year: 2020 PMID: 32411249 PMCID: PMC7212324 DOI: 10.1155/2020/2938258
Source DB: PubMed Journal: Int J Cell Biol ISSN: 1687-8876
List of antibodies investigated, dilutions and antigen retrieval methods applied in the immunohistochemical analysis.
| Antibody | Clonality | Manufacturer | Dilution | Antigen retrieval |
|---|---|---|---|---|
| Cytokeratin | Clone AE1/AE3 | Invitrogen®, Thermo Fisher Scientific® | 1/200 | Water bath/20 min |
| Vimentin | Clone V9 | DAKO®, Agilent Technologies® | 1/1200 | Water bath/20 min |
| CD31 | Clone JC70A | DAKO®, Agilent Technologies® | 1/200 | Pepsine |
| Synaptophysin | Clone SP11 | Thermo Fisher Scientific® | 1/100 | Water bath/20 min |
| c-Kit | Polyclonal | DAKO®, Agilent Technologies® | 1/450 | Water bath/20 min |
| GFAP | Polyclonal | Millipore® | 1/2000 | Water bath/20 min |
Figure 1Magnification: 100x; Scale Bar: 100 μm. (a) OM fragment plated by the explant method after enzymatic digestion. 1 week after plating, cells with morphological characteristics of MSCs irradiating from the explant can be observed; (b)–(e): morphology of OM-MSCs in culture: (b) P2, 30–40% confluence; (c) P5, 50–60% confluence; (d) P7, 70–80% confluence, ideal moment for passage; (e) P9, 90–100% confluence.
Figure 2(a) OM-MSCs' growth curve over 35 days (15 passages); (b) Variation of % cell viability over 35 days (15 passages).
Figure 3Cell growth of OM-MSCs over 10 days of culture in P2-P3 (a), P6-P7 (b), and P13-P14 (c).
Figure 4PDT for the different passages (mean ± SEM).
Figure 5CFU assay: observation of individualized colonies in a 6-well tissue culture treated plate, stained with crystal violet solution.
Figure 6Cell differentiations. Magnification: 100x; Scale bar: 100 μm. Adipogenic differentiation: (a) control; (b) presence of large round shaped cells (black arrow) and red stained lipid vacuoles inside the cytoplasm (white arrow); chondrogenic differentiation: (c) control; (d) presence of chondrogenic aggregate and extracellular matrix stained in blue (black arrow); osteogenic differentiation: (e) control; (f) presence of calcium containing osteocytes (black arrow) and extracellular calcium deposits (white arrow) stained in red; neurogenic differentiation: (g) control; (h) 24 h after addition of neurogenic induction medium, the cells acquired a neuroglial-like shape with development of dendrite (black arrow) and axonal-like (white arrow) cell structures (i) 72 h after addition of neurogenic induction medium.
Ct, ΔCt, ΔΔCt and RQ values for all genes under study for P4 and P6. nd = nondefined.
| Target gene | P4 | P6 | |||||
|---|---|---|---|---|---|---|---|
| Ct average OM-MSCs | ΔCt OM-MSCs | Ct average OM-MSCs | ΔCt OM-MSCs | ΔΔCt | RQ | Regulation | |
| Nanog | 35.9 ± 0.9 | 9.7 | 38.2 ± 0.0 | 13.5 | 5.4 | 0.0 | ↓ |
| Oct4 | 35.3 ± 0.0 | 9.1 | 36.5 ± 0.0 | 11.9 | 4.3 | 0.1 | ↓ |
| Sox2 | 36.0 ± 0.0 | 9.8 | 36.0 ± 0.0 | 11.3 | 3.0 | 0.1 | ↓ |
| CD105 | 33.9 ± 0.0 | 7.7 | 34.5 ± 0.0 | 9.8 | 3.7 | 0.1 | ↓ |
| CD90 | 26.2 ± 0.2 | −1.5 | 26.4 ± 0.0 | 1.7 | 3.2 | 0.1 | ↓ |
| CD73 | 32.9 ± 0.3 | 6.7 | 32.9 ± 0.3 | 8.2 | 3.0 | 0.1 | ↓ |
| CD44 | 29.4 ± 0.1 | 3.2 | 28.1 ± 0.1 | 3.4 | 1.7 | 0.3 | ↓ |
| CD45 | nd | nd | nd | nd | nd | nd | nd |
| CD34 | nd | nd | nd | nd | nd | nd | nd |
| BSP | 40.6 ± 0.0 | 14.4 | 35.8 ± 0.0 | 11.1 | −1.8 | 3.5 | ↑ |
| Runx2 | 35.1 ± 0.6 | 8.9 | 31.8 ± 0.0 | 7.1 | −0.3 | 1.2 | N |
| Coll II | 36.8 ± 0.0 | 10.6 | 30.3 ± 0.3 | 5.7 | −3.4 | 10.5 | ↑ |
| Aggrecan | 36.6 ± 0.6 | 10.4 | 31.6 ± 0.4 | 7.0 | −1.9 | 3.8 | ↑ |
| Ap−2 | 33.8 ± 0.4 | 7.6 | 27.8 ± 0.1 | 3.2 | −2.9 | 7.5 | ↑ |
| AdipoQ | nd | nd | nd | nd | nd | nd | nd |
| NGF | 36.9 ± 0.7 | 10.7 | 31.7 ± 0.4 | 7.0 | −2.2 | 4.5 | ↑ |
| GDNF | 34.4 ± 1.7 | 8.2 | 33.0 ± 0.0 | 8.4 | 1.7 | 0.3 | ↓ |
| Tenomodulin | 35.0 ± 0.0 | 8.8 | 35.0 ± 0.0 | 10.4 | 3.0 | 0.1 | ↓ |
| Desmin | 36.2 ± 0.0 | 10.1 | 36.3 ± 0.1 | 11.6 | 3.1 | 0.1 | ↓ |
Figure 7ΔCt Values for the different genes under study in OM-MSCs for P4 and P6. Higher delta-CT values represent lower expression (mean ± SEM).
Figure 8OM-MSCs' karyotype (P8), showing structural normality, normal number of chromosomes (42, XY) and absence of neoplastic alterations. These characteristics demonstrate the chromosomal stability of these cells.
Percentage of normal karyotypes and mitotic indexes of OM-MSCs in P5, P8, and P11.
| Passage | % Cells with normal karyotype (42, XY) | Mitotic Index |
|---|---|---|
| P5 | 85% | Normal |
| P8 | 62% | Normal |
| P11 | 58, 80% | Low |
Figure 9Immunolabeling of rat OM-MSCs (P5), Magnification: 600x: (a) AE1/AE3 (0); (b) Vimentin (+++); (c) CD31 (0); (d) Synaptophysin (+), (the black arrow highlights focal and membranous positive immunostaining); (e) c-Kit (++); (f); GFAP (+++). Insets show the respective negative controls for each immunomarker.
Mean normalized concentration of each biomarker in the CM of OM-MSCs (mean ± SEM).
| Biomarker | Mean normalized concentration |
|---|---|
| IL-4 | 0.34 ± 0.11 |
| IL-2 | 0.4 ± 0.22 |
| IL-6 | 0.32 ± 0.3 |
| IFN- | 0.07 ± 0.1 |
| IL-18 | 0.08 ± 0.10 |
| MCP-1 | 0.13 ± 0.9 |
| TNF- | 0.31 ± 0.04 |
| VEGF | 0.19 ± 0.13 |
Figure 10Normalized concentration of each biomarker in the conditioned medium of OM-MSCs (mean ± SEM).